A newly-published review is calling for more randomized trials to be carried out in order to further strengthen the relationship between obstructive sleep apnea (OSA) and cardiovascular mortality.

Randomized control trials (RCTs) do not show long-term benefits of continuous positive airway pressure (CPAP) devices on cardiovascular outcomes, say researchers, who point out post-hoc analyses demonstrates improved outcomes in those who use CPAP adequately. 

Administering a new high-sensitivity cardiac troponin test (hs-cTn) bedside to emergency department (ED) patients, with a 0/1-hour diagnostic algorithm, moderately reduces ED length of stay and is just as safe as centralized testing, results from the WESTCOR-POC trial show. 

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor has clinical non-inferiority and offers a significant reduction in adverse clinical events than a contemporary drug-eluting stent (DES), according to new data from the INFINITY-SWEDEHEART trial.

Findings from the REC-CAGEFREE trial presented at the 2024 European Society of Cardiology (ESC) Congress suggest that drug-coated balloon angioplasty is less effective in addressing previously untreated non-complex coronary lesions when compared to second generation drug eluting stents (DES).

Optical coherence tomography (OCT)-guidance improved clinical outcomes and cut the risk of cardiac death, myocardial infarction (MI), stent thrombosis and the need for revascularization by 38% in percutaneous coronary intervention (PCI) procedures, compared to conventional angiography-led stenting, in the South Korean OCCUPI trial. 

Pulmonary vessel isolation (PVI) with cryoballoon ablation significantly reduced atrial fibrillation (AF) burden, compared with that in the sham procedure, accompanied by clinically important in symptoms and quality of life, report investigators from the SHAM-PVI trial.

Removal of fasting requirements before cardiac procedures is not only safe, but also results in more satisfied patients, say the SCOFF trial investigators. 

Complete revascularization is the most beneficial option for older patients with ST-elevation myocardial infarction (STEMI) and multivessel disease versus culprit-only coronary artery revascularization, according to a new meta-analysis of patients up to 4-years post intervention.